About

External experts are sought after advisors for life science companies, where they make informed critical decisions along the entire product lifecycle of a drug.
These experts use the knowledge and experience they acquired over the course of their careers to help companies address challenges like identifying unmet medical needs, clinical trial design, stratification of patient populations, label extensions, product positioning, regulatory challenges, and many others.
They can also serve as the scientific face of the organization, e.g., by discussing trial results during conferences and/or co-authoring scientific publications.
Traditionally, these external experts have been referred to as “opinion leaders”, or “key opinion leaders” (KOLs) and recognized thanks to their proven expertise and scientific exposure in activities such as publications or speaking at relevant conferences.

The purpose of this training is defining a list of objective and measurable criteria to be used for KOLs' mapping, regardless the therapeutic area, to support pharma & biotech medical professionals in creating a network of experts with whom establish a trustful, durable and fruitful collaboration.

  • Rationale for KOL mapping, using a standardize approach
  • Criteria for KOL identification: objective versus subjective ones
  • KOL identification & segmentation in a pyramid
  • KOL mapping examples

Medical Affairs representatives of pharma and biotech who want to strengthen his/her ability in creating a KOL solid network.

Training will be based on interactive presentations with discussion and Q&A sessions.
A series of real time examples and case studies will be reviewed.

Lecturers
Gabriella Pasciullo
Info

Gabriella Pasciullo

Senior Regional Medical Director, Italy & Iberia at Pharming

Graduated in Medicine and Surgery and specialized in Medical Toxicology, in 2011 Master in Business & Administration at Bocconi University in Milan. After conducting research in pain treatment & drug abuse at the University of Modena, I entered the pharma space in 2005. At the beginning worked as MSL at Pfizer first and then at GSK. I progressed my professional career in GSK Medical Affairs till 2015, moving from a Medical Advisor position to the role of Italian Medical Manager for the entire Adolescent / Adult Vaccine portfolio, afterwards to Italian Country Medical Head of Global Business Unit for Immunotherapeutic Oncology Vaccines. More recently I launched, as the first ever employee in Europe, the Regional & country set-up of bluebird bio Inc. – American biotech actively engaged in the research of gene and cellular therapies for the treatment of rare genetic or oncological diseases in the hematological and CNS area – in which I was prior Medical Director in Italy and then European Medical Lead for CALD & GT. Now, working as Sr. Regional Medical Dr. Italy & Iberia at Pharming, I’m actively contributing the company products in rare diseases clinical development and, eventually, local registration through scientific support in the creating respective product technical dossiers, communication materials and publications, as well as in the organization of congresses, symposia and advisory boards.


This online training consists of 1 module:

11 November  2022 from 9:00 am to 1:00 pm CET

Some days before the online training you will receive all details about the connection.

The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.

Early Bird: € 465,00* (until 11 October 2022)

Ordinary: € 595,00*

Freelance – Academy – Public Administration**: € 350,00*

* for Italian companies: +22% VAT

** Early Bird discount not applicable to Freelance – Academy – Public Administration fee

The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.

Registrati

Ticket not available


Printable Version
At the end of the training, you will be able to
Risultato atteso
Approach with a systematic methodology KOLs’ mapping and engagement, regardless the therapeutic area in scope and product life cycle phase.

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform. 

LS Academy will provide the access link to the virtual platform a few days before the training.

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>